PTC Therapeutics Names Eric Pauwels SVP & General Manager Commercial Operations, Americas

News provided by

Apr 08, 2015, 08:00 ET

SOUTH PLAINFIELD, N.J., April 8, 2015 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT), today announced the appointment of Eric Pauwels as Senior Vice President and General Manager Commercial Operations, Americas. Eric will be responsible for the commercial strategy, organizational build out and launch of Translarna in the US, Canada and Latin America.

"Eric is an exceptional individual who has successfully launched more than 20 biopharmaceutical specialty and rare disease products globally," said Mark Rothera, Chief Commercial Officer, PTC Therapeutics, Inc. "His strong track record of strategic leadership, operational execution and global commercial expertise, particularly in orphan drug launches, will be extremely valuable as we work toward the launch of Translarna in the United States and other key markets. I am proud of the high caliber commercial leadership team we have built at PTC that will ensure we bring Translarna to patients around the world as quickly as possible."

Eric brings 33 years of global healthcare experience from several top-tier US and global pharmaceutical companies. Most recently, Eric was the Chief Commercial Officer at NPS Pharmaceuticals and President of NPS Pharmaceuticals International. At NPS, Eric built global commercial operations for the launch of Gattex/Revestive and prepared the pre-launch strategy for Natpara, both orphan biological therapies approved by the FDA for patients suffering from rare gastrointestinal and endocrine diseases. From 2005 to 2010, Eric served as Senior Vice President, Global Commercial Operations, at Shire Human Genetic Therapies, with oversight of more than 400 employees in 30 countries and $800 million in revenues. Eric also held global marketing and general management functions in the US, Europe and China with Shire, Bayer, Fournier and J&J. Eric holds a BSc. degree from California State Polytechnic University.

"I am very pleased to be joining a dynamic PTC team during this exciting time as the company prepares for commercial launch of Translarna in the United States, Canada, Brazil and other key Latin American markets," said Mr. Pauwels. "The company is proud of the Translarna launch progress in Europe and I look forward to building out and leading our PTC Americas team to ensure every patient has access to this first-in-class therapy to treat the underlying cause of nonsense mutation Duchenne muscular dystrophy as rapidly as possible."

About PTC Therapeutics, Inc.
PTC is a global biopharmaceutical company focused on the discovery, development and commercialization of orally administered, proprietary small molecule drugs targeting an area of RNA biology we refer to as post-transcriptional control. Post-transcriptional control processes are the regulatory events that occur in cells during and after a messenger RNA is copied from DNA through the transcription process. PTC has received conditional marketing authorization in the European Economic Area for Translarna for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients aged five years and older. PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare disorders, oncology and infectious diseases. PTC has discovered all of its compounds currently under development using its proprietary technologies. PTC plans to continue to develop these compounds both on its own and through selective collaboration arrangements with leading pharmaceutical and biotechnology companies. For more information on the company, please visit our website www.ptcbio.com.

For More Information:
Investors:
Emily Hill
+1(908) 912-9327
[email protected]

Media:
Jane Baj
+1 (908) 912-9167
[email protected]

Forward Looking Statements:
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements, other than those of historical fact, contained in this release, including statements regarding the future expectations, plans and prospects for PTC; the timing and scope of PTC's commercial and early access program launches; the rate and degree of market acceptance and clinical utility of Translarna; PTC's estimates regarding the potential market opportunity for Translarna, including the size of eligible patient populations and PTC's ability to identify such patients; our strategy, future operations, future financial position, future revenues or projected costs; and objectives of management, are forward-looking statements. Other forward-looking statements may be identified by the words "plan," "guidance," "anticipate," "believe," "estimate," "expect," "intend," "may," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions.

PTC's actual results, performance or achievements could differ materially from those expressed or implied by forward-looking statements it makes as a result of a variety of risks and uncertainties, including those related to its ability to commercialize Translarna in general and specifically as a treatment for nmDMD, including its ability to successfully negotiate favorable pricing and reimbursement processes on a timely basis in the countries in which it may obtain regulatory approval, including the countries in the European Economic Area; expectations for regulatory approvals; PTC's scientific approach and general development progress; the eligible patient base and commercial potential of Translarna and PTC's other product candidates and the factors discussed in the "Risk Factors" section of PTC's most recent Annual Report on Form 10-K as well as any updates to these risk factors filed from time to time in PTC's other filings with the SEC. You are urged to carefully consider all such factors. The forward-looking statements contained herein represent PTC's views only as of the date of this press release and PTC does not undertake or plan to update or revise any such forward-looking statements to reflect actual results or changes in plans, prospects, assumptions, estimates or projections, or other circumstances occurring after the date of this release except as required by law.

SOURCE PTC Therapeutics, Inc.